Literature DB >> 28552430

Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies and Outcome.

Tatyana Weitsman1, Giora Weisz1, Rivka Farkash1, Marc Klutstein1, Adi Butnaru1, David Rosenmann1, Tal Hasin2.   

Abstract

INTRODUCTION: Pulmonary hypertension has many causes. While it is conventionally thought that the most prevalent is left heart disease, little information about its proportion, causes, and implications on outcome is available.
METHODS: Between 1993 and 2015, 12,115 of 66,949 (18%) first adult transthoracic echocardiograms were found to have tricuspid incompetence gradient ≥40 mm Hg, a pulmonary hypertension surrogate. Left heart disease was identified in 8306 (69%) and included valve malfunction in 4115 (49%), left ventricular systolic dysfunction in 2557 (31%), and diastolic dysfunction in 1776 (21%). Patients with left heart disease, as compared with those without left heart disease, were of similar age, fewer were females (50% vs 63% P <.0001), and they had higher tricuspid incompetence gradient (median 48 mm Hg [interquartile range 43, 55] vs 46 mm Hg [42, 54] P <.0001). In reviewing trends over 20 years, the relative proportions of systolic dysfunction decreased and diastolic dysfunction increased (P for trend <.001), while valve malfunction remained the most prevalent cause of pulmonary hypertension with left heart disease. Independent predictors of mortality were age (hazard ratio [HR] 1.05; 95% CI, 1.04-1.05; P <.0001), tricuspid incompetence gradient (HR 1.02; 95% CI, 1.01-1.02, P <.0001 per mm Hg increase), and female sex (HR 0.87; 95% CI, 0.83-0.91, P <.0001).
RESULTS: Overall, left heart disease was not an independent risk factor for mortality (HR 1.04; 95% CI, 0.99-1.09; P = .110), but patients with left ventricular systolic dysfunction and with combined systolic dysfunction and valve malfunction had increased mortality compared with patients with pulmonary hypertension but without left heart disease (HR 1.30; 95% CI, 1.20-1.42 and HR 1.44; 95% CI, 1.33-1.55, respectively; P <.0001 for both).
CONCLUSIONS: Pulmonary hypertension was found to be associated with left heart disease in 69% of patients. Among these patients, valve malfunction and diastolic dysfunction emerged as prominent causes. Left ventricular dysfunction carries additional risk to patients with pulmonary hypertension.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diastolic dysfunction; Heart valve disease; Survival; Systolic dysfunction; Tricuspid incompetence gradient

Mesh:

Year:  2017        PMID: 28552430     DOI: 10.1016/j.amjmed.2017.05.003

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest VE /VCO2 and ETCO2 identify pulmonary vascular disease.

Authors:  Farhan Raza; Naga Dharmavaram; Timothy Hess; Ravi Dhingra; James Runo; Amy Chybowski; Callyn Kozitza; Supria Batra; Evelyn M Horn; Naomi Chesler; Marlowe Eldridge
Journal:  Clin Cardiol       Date:  2022-04-14       Impact factor: 3.287

2.  Pulmonary Hypertension in Aortic and Mitral Valve Disease.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2018-05-23

3.  Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.

Authors:  Javier Bermejo; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subías; José Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Eduardo de Teresa; José R González-Juanatey; Arturo Evangelista; Teresa Mombiela; Ana González-Mansilla; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  Eur Heart J       Date:  2018-04-14       Impact factor: 29.983

4.  Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.

Authors:  Danielle Louis E Villanueva; Ruth Divine Agustin; Elmer Jasper Llanes
Journal:  Cardiol Res       Date:  2019-11-24

5.  Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival.

Authors:  Javier Bermejo; Ana González-Mansilla; Teresa Mombiela; Ana I Fernández; Pablo Martínez-Legazpi; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subias; J Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Manuel Jiménez-Navarro; José R González-Juanatey; Arturo Evangelista; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

Review 6.  Pulmonary Arterial Hypertension and Adverse Outcomes after Kidney Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Crischentian Brinza; Adrian Covic; Anca Elena Stefan; Mariana Floria; Iolanda Valentina Popa; Dragos-Viorel Scripcariu; Alexandru Burlacu
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

7.  Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography.

Authors:  Daniel X Augustine; Lindsay D Coates-Bradshaw; James Willis; Allan Harkness; Liam Ring; Julia Grapsa; Gerry Coghlan; Nikki Kaye; David Oxborough; Shaun Robinson; Julie Sandoval; Bushra S Rana; Anjana Siva; Petros Nihoyannopoulos; Luke S Howard; Kevin Fox; Sanjeev Bhattacharyya; Vishal Sharma; Richard P Steeds; Thomas Mathew
Journal:  Echo Res Pract       Date:  2018-09

8.  Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil.

Authors:  Ning Xu; Shu-Ting Huang; Kai-Peng Sun; Zeng-Chun Wang; Hua Cao; Qiang Chen
Journal:  BMC Cardiovasc Disord       Date:  2020-11-03       Impact factor: 2.298

9.  The effect of transcatheter aortic valve implantation on pulmonary artery pressures in a patient suffering from chronic heart failure: a case report.

Authors:  Sumant P Radhoe; Jesse F Veenis; Nicolas M Van Mieghem; Jasper J Brugts
Journal:  Eur Heart J Case Rep       Date:  2021-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.